Fortress Biotech Inc. (FBIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily pay $16 million in deferred FBIOP preferred dividends. FBIOP dividends, deferred for nearly two years, could total $4.69 per share if paid by June 15, 2026, benefiting significant insider holders.
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO's subsidiaries give it optionality across multiple subsidiaries, equity stakes, and royalty streams. FBIO's Journey Medical assets give it its branded dermatology portfolio. The newly approved Emrosi provides near-term revenues.
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Fortress Biotech (FBIO) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.43 per share. This compares to a loss of $0.76 per share a year ago.
Fortress Biotech Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| WTM W. Travis McKinney HB Wealth Management LLC | 120,175 | $444,647.5 | $334,086.5 | -$110,561 | -24.86% |
Fortress Biotech Inc. (FBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fortress Biotech Inc. ever had a stock split?
Fortress Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lindsay Allan Rosenwald CEO | NASDAQ (CM) Exchange | 34960Q109 CUSIP |
| US Country | 101 Employees | - Last Dividend | 10 Oct 2023 Last Split | 17 Nov 2011 IPO Date |
Overview
Fortress Biotech, Inc. is a leading biopharmaceutical company based in Bay Harbor Islands, Florida, specializing in the development of innovative dermatology and pharmaceutical and biotechnology products primarily for the U.S. market. The company's business strategy involves marketing approved dermatological products while also advancing a diverse pipeline of late-stage and early-stage product candidates targeting various medical conditions and diseases. Formally known as Coronado Biosciences, Inc., the company underwent a rebranding to Fortress Biotech, Inc. in April 2015. Since its inception in 2006, Fortress Biotech has established multiple collaboration arrangements with universities, research institutes, and pharmaceutical companies, underlining its commitment to combatting serious health issues through advanced biotechnological research and development.
Products and Services
Marketed Dermatology Products:
- Qbrexza: A medicated cloth towelette designed for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweating.
- Accutane Capsules: Prescribed for severe recalcitrant nodular acne, these capsules represent a potent therapy for those unresponsive to conventional treatments.
- Amzeeq: A topical formulation for severe acne vulgaris, offering a novel therapeutic approach to manage this widespread skin condition.
- Zilxi: A topical foam indicated for various dermatological uses.
- Exelderm Cream: A cream for topical application aimed at treating specific dermatological conditions.
- Targadox: An oral doxycycline drug that serves as adjunctive therapy for severe acne, highlighting the company's focus on acne treatments.
- Luxamend: A wound care cream, showcasing Fortress Biotech's entry into therapeutic wound management.
Development Pipeline:
- Intravenous Tramadol: In late-stage development for post-operative acute pain management.
- CUTX-101: An injection under development for treating Menkes disease, a genetic disorder affecting copper levels in the body.
- Cosibelimab: A late-stage candidate for the treatment of metastatic cancers, representing the company's foray into oncology.
- Olafertinib: Targeting patients with EGFR mutation-positive NSCLC, highlighting the company's commitment to precision medicine in lung cancer.
- CAEL-101: Designed for treating amyloid light chain amyloidosis, a rare disease characterized by the deposition of amyloid in organs.
- Triplex vaccine: A vaccine for cytomegalovirus to prevent infection, especially in immunocompromised individuals.
- DFD-29: Under development for rosacea, offering a new therapeutic option for those suffering from this chronic skin condition.
Early Stage and Preclinical Candidates: The company’s early-stage and preclinical product candidate portfolio include novel therapies for gout (Dotinurad), B-cell non-Hodgkin lymphoma (MB-106), glioblastoma (MB-101, MB-108, MB-109), and several other diseases, demonstrating Fortress Biotech’s broad research and development efforts across various areas of high unmet medical need.
